Related Experiment Videos
Contact eczema produced by a beta-adrenergic blocking agent (alprenolol)
Contact Dermatitis
|August 1, 1978
Summary
Alprenolol, a beta-adrenergic blocking agent, is a potent contact allergen causing allergic contact eczema in pharmaceutical workers. Even after removal from exposure, new cases emerged, indicating its strong sensitizing potential.
Area of Science:
- Occupational Dermatology
- Pharmaceutical Safety
Background:
- Allergic contact eczema is a significant occupational health concern in the pharmaceutical industry.
- Beta-adrenergic blocking agents, like alprenolol, are used in medication but can pose risks.
Purpose of the Study:
- To report cases of allergic contact eczema caused by alprenolol (Aptin).
- To investigate the sensitization potential and clinical presentation of alprenolol-induced eczema.
Main Methods:
- Case series reporting on 14 pharmaceutical workers with eczema.
- Clinical observation of skin reactions and sensitization induction time.
- Assessment of potential irritant reactions in mucous membranes.
Main Results:
- 14 workers developed florid eczema, with 13 cases showing sensitization within a year.
- Reactions were reproducible with small alprenolol quantities; one case showed reaction after oral ingestion.
- Despite workplace controls, new cases persisted, suggesting high allergenicity.
Conclusions:
- Alprenolol is identified as a very strong contact allergen.
- Occupational exposure necessitates stringent control measures to prevent alprenolol-induced eczema.
- Further investigation into non-allergic mucous membrane symptoms is warranted.